First Capital Advisors Group’s AbbVie ABBV Stock Holding History

First Capital Advisors Group’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	$288K	Sell	2,140 -16	-0.7%	-$2.35K	0.15%	111
2023 Q1	$344K	Buy	2,156 +13	+0.6%	+$1.99K	0.22%	98
2022 Q4	$346K	Sell	2,143 -968	-31%	-$148K	0.23%	102
2022 Q3	$418K	Buy	3,111 +378	+14%	+$54.2K	0.35%	78
2022 Q2	$419K	Buy	+2,733	New	+$418K	0.29%	87
2018 Q4	$1.2M	Buy	12,967 +1,167	+10%	+$103K	0.9%	27
2018 Q3	$1.12M	Sell	11,800 -144	-1%	-$13.7K	0.68%	32
2018 Q2	$1.11M	Sell	11,944 -468	-4%	-$45.7K	0.73%	29
2018 Q1	$1.18M	Sell	12,412 -2,051	-14%	-$225K	0.68%	31
2017 Q4	$1.4M	Sell	14,463 -224	-2%	-$21.1K	0.88%	31
2017 Q3	$1.3M	Sell	14,687 -3,709	-20%	-$282K	0.9%	31
2017 Q2	$1.33M	Sell	18,396 -1,530	-8%	-$103K	0.91%	28
2017 Q1	$1.3M	Buy	19,926 +2,092	+12%	+$132K	0.97%	23
2016 Q4	$1.12M	Buy	+17,834	New	+$1.09M	1.03%	24

Other funds holding ABBV

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

First Capital Advisors Group's ABBV Position: Q2 2023 in Review

First Capital Advisors Group reduced its AbbVie (ABBV) stake by 0.74% in Q2 2023, selling an estimated $2.35K and leaving 2,140 shares worth $288K. The position accounts for 0.15% of the portfolio, ranked #111.

First Capital Advisors Group first reported a position in ABBV in Q4 2016 and has held it in 14 quarters since. The position peaked at $1.4M in Q4 2017. 3,076 funds tracked by Wall St. Rank hold ABBV as of Q2 2023.

First Capital Advisors Group held 2,140 shares of AbbVie worth $288K as of Q2 2023.
First Capital Advisors Group sold 16 AbbVie shares in Q2 2023, an estimated $2.35K.
AbbVie made up 0.15% of First Capital Advisors Group's portfolio in Q2 2023, its #111 holding.
First Capital Advisors Group first reported a position in AbbVie in Q4 2016 and has held it in 14 quarters since.
First Capital Advisors Group's AbbVie position peaked at $1.4M in Q4 2017.
3,076 funds tracked by Wall St. Rank held AbbVie as of Q2 2023.

Based on First Capital Advisors Group's 13F filing for Q2 2023, filed 15 Aug 2023.